The restriction of Monacolins under 3 mg per day implies the imminent research to find alternative solutions to formulate the new generation of supplements for cholesterol control.

At Sochim, we have been looking for alternatives and finally we have found an interesting proposal: Commiphora mukul, known also as Guggul, a tree native to southern Pakistan, Bangladesh and western India used in Ayurvedic medicine. The gum-oleoresin obtained from the bark of the branches of the Guggul contains plant steroids (Guggulsterones) that can lower cholesterol and triglycerides. Guggulsterones exist as E-guggulsterone and Z-guggulsterone which act as antagonist of the bile acid receptor (BAR), an important regulator of cholesterol homeostasis in the body.

To exploit the best properties of Guggul, Sochim recommends Sabinsa Gugulipid ®, which, unlike generic extracts, is standardized for active guggulsterones Z and E by HPLC method.




There are lots of clinical studies testifying the value of this ingredient which led to the US Patent granted for “the composition for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease”. Gugulipid® has a proven role in reducing Lipoprotein (a) known also as “deadly cholesterol” because it is 10x more dangerous than low density lipoprotein (LDL) and 15x more than total cholesterol. Lp(a) also contributes to plaque deposits inside the arterial walls.



Among the clinical trials conducted, we signal the following related to hypercholesterolemia:


“Delhi Study”: Effect of C. Mukul on serum cholesterol in hyperlipidemic patients
20 Subjects with different types of hyperlipidaemic were treated with Guggul for 30 to 50 weeks.
Type IIa: n=8, Type IIb: n=8, Type III : n=4


Sochim International S.p.A. is a proud partner of Sabinsa Corporation.

Write to us at to find out more.